The vaccine candidate "encodes the SARS-CoV-2 Spike (S) protein and uses novel Fusogenix technology for delivery," Aegis Life said. The next-generation gene delivery technology delivers DNA information inside cells, which is needed to make the viral protein for VAX-001 work. The trial is being conducted at the Canadian Center for Vaccinology and the IWK Health Centre, both in Halifax, Nova Scotia.
A participant receives a dose marking the start of phase I trials for Aegis Life/Entos Pharmaceuticals' COVID-19 DNA vaccine, Covigenix VAX-001. Image courtesy of Aegis Life.
The two firms have also developed a second vaccine candidate, Covigenix VAX-002, which is now in preclinical studies and is intended as a pancoronavirus and emerging variant vaccine, they said.
Copyright © 2021 scienceboard.net